Disintegrin and Metalloproteinase with Thrombospondin Motifs (ADAMTS) enzymes are a family of secreted metalloproteases that play critical roles in the remodeling and homeostasis of the extracellular matrix (ECM). ADAMTS-17 is one of the members of this family, participating in the breakdown of a variety of ECM components such as proteoglycans, collagens, and other matrix constituents. Unlike membrane-anchored ADAMs, ADAMTS enzymes are secreted and hence act in the extracellular space. The regulation of ADAMTS-17 is multi-faceted, influenced by various factors including gene expression, substrate availability, and modulation by other signaling pathways. Epigenetic changes, such as DNA methylation or histone modification, can also influence the expression of ADAMTS-17, as can specific growth factors and cytokines that operate through complex signaling networks.
ADAMTS-17 activators might work indirectly by inhibiting pathways that normally suppress ADAMTS-17 activity or by altering the epigenetic landscape to favor gene expression. They might also operate by modulating the availability of substrates within the ECM, which ADAMTS-17 acts upon, or by stabilizing the ECM structure itself. Molecules that act as Reactive Oxygen Species (ROS) scavengers could influence the oxidative environment, potentially supporting optimal enzyme activity. Other molecules may interfere with competing pathways, such as Notch or TGF-β signaling, to fine-tune the activity levels of ADAMTS-17. Overall, the chemical biology of ADAMTS-17 activators is complex, necessitating multi-disciplinary approaches to fully elucidate the mechanisms involved.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
A derivative of vitamin A that can modulate gene expression and thereby potentially affect ADAMTS levels or activity. | ||||||
Heparin | 9005-49-6 | sc-507344 | 25 mg | $119.00 | 1 | |
This glycosaminoglycan can interact with some ADAMTS proteins and influence their activity. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
Phorbol Esters can upregulate the expression of some ADAMTS proteins, although they are mainly used experimentally. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
A TGF-β inhibitor that can potentially upregulate certain ADAMTS enzymes by suppressing TGF-β signaling pathways that may downregulate ADAMTS expression. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
An HDAC inhibitor that may facilitate ADAMTS gene expression by altering the epigenetic landscape. | ||||||
GM 6001 | 142880-36-2 | sc-203979 sc-203979A | 1 mg 5 mg | $77.00 $270.00 | 55 | |
An MMP inhibitor that may help in maintaining the ECM substrates available for ADAMTS activity, thus potentially indirectly activating it. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
PDGF Small Molecule Inhibitors could potentially influence ADAMTS activity by interfering with growth factor-mediated ECM remodeling. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
PDGF Small Molecule Inhibitors could potentially influence ADAMTS activity by interfering with growth factor-mediated ECM remodeling. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
PDGF Small Molecule Inhibitors could potentially influence ADAMTS activity by interfering with growth factor-mediated ECM remodeling. | ||||||
Esculetin | 305-01-1 | sc-200486 sc-200486A | 1 g 5 g | $44.00 $212.00 | 7 | |
A naturally occurring coumarin that has been shown to inhibit LOX activity. Lysyl oxidase (LOX) inhibitors target the enzyme responsible for cross-linking collagen and elastin fibers in the extracellular matrix (ECM) and stabilize the ECM, affecting the substrate availability for ADAMTS. | ||||||